{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T17:53:32Z","timestamp":1772042012040,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2002,7,1]],"date-time":"2002-07-01T00:00:00Z","timestamp":1025481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":6399,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2002,7]]},"DOI":"10.1093\/annonc\/mdf183","type":"journal-article","created":{"date-parts":[[2002,7,28]],"date-time":"2002-07-28T22:39:17Z","timestamp":1027895957000},"page":"1072-1079","source":"Crossref","is-referenced-by-count":33,"title":["Multicenter non-randomized phase II study of raltitrexed (Tomudex) and oxaliplatin in non-pretreated metastatic colorectal cancer patients"],"prefix":"10.1016","volume":"13","author":[{"given":"J.-F.","family":"Seitz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Bennouna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Paillot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Gamelin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Fran\u00e7ois","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Conroy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-L.","family":"Raoul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Becouarn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Bertheault-Cvitkovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Ychou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Nasca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Fandi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Barthelemy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-Y.","family":"Douillard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdf183_bb0010","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJM200009283431302","article-title":"Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer","volume":"343","author":"Saltz","year":"2000","journal-title":"Irinotecan Study Group. N Engl J Med"},{"key":"10.1093\/annonc\/mdf183_bb0015","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0140-6736(00)02034-1","article-title":"Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial","volume":"355","author":"Douillard","year":"2000","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdf183_bb0020","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2000.18.16.2938","article-title":"Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer","volume":"18","author":"De Gramont","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdf183_bb0025","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1200\/JCO.2000.18.1.136","article-title":"Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer","volume":"18","author":"Giacchetti","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdf183_bb0030","first-page":"4","article-title":"Oxaliplatin: mechanism of action and antineoplastic activity","volume":"25","author":"Raymond","year":"1998","journal-title":"Semin Oncol"},{"key":"10.1093\/annonc\/mdf183_bb0035","first-page":"523","article-title":"Effect of loss of DNA mismatch repair on cisplatin oxaliplatin and JM 216 sensitivity","volume":"38","author":"Fink","year":"1997","journal-title":"Proc Am Assoc Cancer Res"},{"key":"10.1093\/annonc\/mdf183_bb0040","first-page":"291","article-title":"Oxaliplatin (LOHP) and cisplatin (CDDP) in combination with 5FU specific thymidine synthase (TS) inhibitors (AG337 ZD169) and topoisomerase I (Topo-I) inhibitors (SN38 CPT-11) in human colorectal ovarian and breast cancer","volume":"37","author":"Raymond","year":"1996","journal-title":"Proc Am Assoc Cancer Res"},{"key":"10.1093\/annonc\/mdf183_bb0045","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/bjc.1998.421","article-title":"Mature results from three large controlled studies with raltitrexed (Tomudex)","volume":"77","author":"Cunningham","year":"1998","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdf183_bb0050","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1200\/JCO.1998.16.8.2739","article-title":"Phase II trial of oxaliplatin as first line chemotherapy in metastatic colorectal cancer patients","volume":"16","author":"Becouarn","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdf183_bb0055","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1200\/JCO.2000.18.11.2293","article-title":"Phase I, dose-finding, and pharmacokinetic study of raltitrexed combined with oxaliplatin in patients with advanced cancer","volume":"18","author":"Fizazi","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdf183_bb0060","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","article-title":"Reporting results of cancer treatment","volume":"47","author":"Miller","year":"1981","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdf183_bb0065","series-title":"Grading of toxicity","first-page":"519","article-title":"Manual of Oncologic Therapeutics","author":"Macdonald","year":"1995"},{"key":"10.1093\/annonc\/mdf183_bb0070","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1093\/annonc\/mdf183_bb0075","first-page":"307a","article-title":"Promising activity of irrinotecan (CPT-11) and raltitrexed (ZD1694) as first line chemotherapy in metastatic colorectal cancer (MCC)","volume":"19","author":"Carnaghi","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdf183_bb0080","first-page":"309a","article-title":"Irinotecan (CPT-11) and raltitrexed (Tomudex) in advanced colorectal cancer: a phase II study","volume":"19","author":"Nobile","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdf183_bb0085","first-page":"120b","article-title":"An ongoing phase II study of raltitrexed (Tomudex) plus irinotecan in advanced colorectal cancer","volume":"20","author":"Escudero","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdf183_bb0090","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1002\/1097-0142(20010401)91:7<1264::AID-CNCR1127>3.0.CO;2-X","article-title":"Oxaliplatin plus raltitrexed in patients with advanced colorectal carcinoma","volume":"91","author":"Scheithauer","year":"2001","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdf183_bb0095","first-page":"116b","article-title":"Raltitrexed combined with oxaliplatin as first-line treatment in patients (p) with advanced colorectal cancer (aCRC). Preliminary data of a phase II study","volume":"20","author":"Garcia-Arroyo","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdf183_bb0100","first-page":"113b","article-title":"Oxaliplatin (OHP) and raltitrexed (RTX) in advanced colorectal cancer (ACRC) patients: a phase II study","volume":"20","author":"Pinto","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdf183_bb0105","first-page":"124a","article-title":"FOLFIRI followed by FOLFOX versus FOLFOX followed by FOLFIRI in metastatic colorectal cancer (MCRC) final results of a phase III study","volume":"20","author":"Tournigand","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdf183_bb0110","first-page":"125a","article-title":"Bolus 5-fluorouracil (5-FU)\/folinic acid (FA) (Mayo) versus weekly high-dose 24 h 5-FU infusion\/FA + oxaliplatin (OXA) in advanced colorectal cancer (CRC) Results of a phase III study","volume":"20","author":"Grothey","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdf183_bb0115","first-page":"373","article-title":"Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis","volume":"356","author":"Buyse","year":"2000","journal-title":"Meta-Analysis Group in Cancer. Lancet"},{"key":"10.1093\/annonc\/mdf183_bb0120","first-page":"145a","article-title":"Raltitrexed (TOM) may replace the de Gramont regimen in combination with oxaliplatin (L-OHP) for the treatment of advanced colorectal cancer","volume":"20","author":"Catalano","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdf183_bb0125","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1023\/A:1008347829017","article-title":"Long term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery","volume":"10","author":"Giacchetti","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdf183_bb0130","series-title":"Cancer of the colon","first-page":"1216","article-title":"Cancer: Principles and Practice of Oncology","author":"Skibber","year":"2001"},{"key":"10.1093\/annonc\/mdf183_bb0135","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1023\/A:1011194712661","article-title":"Second-line treatment with oxaliplatin + raltitrexed in patients with advanced colorectal cancer failing fluoropyrimidine\/leucovorin-based chemotherapy","volume":"12","author":"Scheithauer","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdf183_bb0140","first-page":"578a","article-title":"The combination of raltitrexed (Tomudex) and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study","volume":"19","author":"Fizazi","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"Suppl 4","key":"10.1093\/annonc\/mdf183_bb0145","first-page":"110","article-title":"Raltitrexed and oxaliplatin as first-line treatment of advanced pleural mesothelioma Preliminary data of a phase II study","volume":"11","author":"Maisano","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdf183_bb0150","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1093\/oxfordjournals.annonc.a010800","article-title":"Final results of a randomized trial comparing Tomudex (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer","volume":"7","author":"Cunningham","year":"1996","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdf183_bb0155","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1200\/JCO.1998.16.9.2943","article-title":"Open, randomized multicenter trial of raltirexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer","volume":"16","author":"Cocconi","year":"1998","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375341963872X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375341963872X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/13\/7\/1072\/438292\/mdf183.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T07:36:13Z","timestamp":1582184173000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092375341963872X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,7]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2002,7]]}},"alternative-id":["S092375341963872X"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdf183","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2002,7]]}}}